High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France-Reference-Cited by-同舟云学术

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France

Published:2022-12 Issue:10 Volume:178 Page:999-1010
ISSN:0035-3787
Container-title:Revue Neurologique
language:en
Short-container-title:Revue Neurologique

Author:

Villain N.^ORCID,Planche V.^ORCID,Levy R.

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference47 articles.

1. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects;Villain;Rev Neurol (Paris),2022

2. Aduhelm: Pending EC decision | European Medicines Agency n.d. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/aduhelm (accessed January 18, 2022).

3. Aducanumab for Alzheimer's disease: a regulatory perspective;Nisticò;Pharmacol Res,2021

4. Update on the Phase 4 Confirmatory Study of ADUHELM® | Biogen n.d. https://investors.biogen.com/news-releases/news-release-details/update-phase-4-confirmatory-study-aduhelmr (accessed January 17, 2022).

5. Autorisation de mise sur le marché pour les médicaments - ANSM n.d. https://ansm.sante.fr/page/autorisation-de-mise-sur-le-marche-pour-les-medicaments (accessed January 25, 2022).

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Catastrophe of Intracerebral Hemorrhage Drives the Capillary-Hemorrhage Dementias, Including Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-01-30

2. Estimated effects of amyloid reduction on cognitive change: A Bayesian update across a range of priors;Alzheimer's & Dementia;2023-10-30

3. JAD: A Forum for Philosophy in Science;Journal of Alzheimer's Disease;2023-09-12

4. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease;Advances in Clinical and Experimental Medicine;2023-09-07

5. FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease;Clinical Nuclear Medicine;2023-05-23